- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03850652
Can Prebiotics Support the Treatment of Mild Iron Deficiency by Iron Supplementation
Study Overview
Status
Conditions
Detailed Description
This will be a crossover, placebo controlled, and randomised pilot study in 15 pre-menopausal female individuals with ferritin levels below 40 mcg/l but normal hemoglobin (Hb) and C reactive protein (CRP). The study will last 12 weeks and consist of two separated 4-week randomised intervention treatment periods with a prebiotic (Synergy-1) or placebo (Maltodextrin) in combination with an iron supplement (FeSO4) separated by a 4-week wash-out period. Volunteers will take daily doses of an iron supplement and a prebiotic (Synergy-1) or placebo (Maltodextrin) during the trial excepting in the washout period where the iron supplement and prebiotic/placebo treatments will be discontinued.
This trial will investigate the effects of an iron supplement treatment in combination with a prebiotic food supplement or placebo food supplement. Participants will be required to take one daily tablet of a generic, iron supplement (200 mg FeSO4 equivalent to 65 mg iron) (provided by pharmacy). In addition, participants will be required to take one of the products (prebiotic or placebo) daily at the same time each day. The prebiotic food supplement (supplied by the Beneo company) is a chicory inulin powder produced in Belgium. It has been used in scores of human intervention studies with no adverse effects. Participants will be required to take one 7 g sachet of prebiotic food supplement daily. This will be reconstituted with water and participants will be encouraged to take the sachet at the same time each day. The placebo control food supplement will be maltodextrin. Maltodextrin is a standard placebo product for use in human studies involving prebiotics and has been used safely at this dose, in many trials by ourselves for the last 20 years. The products will be provided as a powder (served in sachets) and identical in texture and appearance. The Beneo company will produce and provide barcoded sachets, blinded to the investigators and volunteers. After all volunteers have completed their study visits and all samples have been analysed by researchers, Beneo will provide information about barcoded sachets. Compliance to food supplement (prebiotic or placebo) will be assessed by recording intake in gastrointestinal (GI) diaries and participants will also be asked to return any unused sachets to the researchers at the end of the each 4-week intervention periods. For participants to be considered compliant and therefore included in the study, they will be required to take the food supplement or placebo at least 6 out of every 7 days of the trial for the week period and return completed questionnaires.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Andrea Monteagudo, PhD
- Phone Number: +44 (0) 118 378 7713
- Email: a.montegudo@reading.ac.uk
Study Locations
-
-
-
Reading, United Kingdom, RG6 6AP
- Recruiting
- University of Reading
-
Contact:
- Andrea Monteagudo, PhD
- Phone Number: +44 (0) 118 378 7713
- Email: a.monteagudo@reading.ac.uk
-
Principal Investigator:
- Gemma E Walton, PhD, BSc
-
Sub-Investigator:
- Andrea Monteagudo, PhD, BSc
-
Principal Investigator:
- Simon Andrews, PhD, BSc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age: 18-50 years
- Gender: Female
- Volunteers agree to sign an informal written consent form
- General good health
- Have ferritin levels below 40 mcg/l
- Normal or borderline-low hemoglobin levels (>11.5g/dL)
Exclusion Criteria:
- Use of antibiotics, prebiotics or probiotics (in food products or as supplements), laxatives, anti-spasmodic, anti-diarrhoea drugs, (e.g. Orlistat, Lactulose) in the last 4 weeks prior to, or during the study period.
- Use of any iron supplement in the last 6 months prior to the study period.
- If participants have received bowel preparation for investigative procedures in the 4 weeks prior to the study.
- Surgical resection of any part of the bowel.
- If participants are taking any medication whose effectiveness could be reduced by the iron administration (e.g. Levodopa, Levothyroxine).
- If participants have any chronic gut disorder/disease, such as inflammatory bowel syndrome (IBS), inflammatory bowel disease (IBD), etc. or other conditions that might affect the gut environment, e.g. coeliac disease.
- If participants are taking any medication that could affect the iron absorption (e.g. lansoprazole, omeprazole).
- If participants are pregnant or are lactating.
- If participants have a body mass index (BMI) > 30 kg/m2.
- Severe allergy or any history of severe abnormal drug reaction, drug or alcohol abuse.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Prebiotic (Synergy-1)
Prebiotic (Synergy-1) + Iron supplement
|
In addition, participants will be required to take one 7 g sachet of prebiotic food supplement daily.
In addition, participants will be required to take one daily tablet of a generic, iron supplement (200 mg FeSO4 equivalent to 65 mg iron) (provided by pharmacy).
|
Placebo Comparator: Maltodextrin
Placebo (Maltodextrin) + Iron Supplement
|
participants will be required to take one 7 g sachet of placebo (maltodextrin) daily.
In addition, participants will be required to take an iron supplement (200 mg FeSO4 equivalent to 65 mg iron) (provided by pharmacy).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the faecal microbiota composition by Next Generation Sequencing (NGS)
Time Frame: 12 weeks intervention
|
Changes in composition of faecal microbiota attributable to prebiotic and iron intervention assessed by Next Generation Sequencing.
|
12 weeks intervention
|
Changes in the concentration (mcg/g) of faecal calprotectin (gut inflammatory marker) during iron intervention using enzyme-linked immunosorbent assays (ELISAs).
Time Frame: 12 weeks intervention
|
Gut inflammation will be evaluated measuring concentration (mcg/g) of calprotectin.
Elevated faecal calprotectin indicates the migration of neutrophils to the intestinal mucosa, which occurs during intestinal inflammation
|
12 weeks intervention
|
Changes in the concentration (pg/mL) of inflammatory markers in plasma during iron intervention using enzyme-linked immunosorbent assays (ELISAs).
Time Frame: 12 weeks intervention
|
Gut inflammation will be also assessed measuring concentration (pg/mL) of gut inflammatory markers as plasma intestinal fatty acid-binding protein and cytokines from plasma (i.e interleukin 6, interleukin 10, tumor necrosis factor alpha).
Samples will be analysed using enzyme-linked immunosorbent assays (ELISAs).
|
12 weeks intervention
|
Changes in faecal microbiota activity measured by using Nuclear magnetic resonance spectroscopy (NMR)
Time Frame: 12 weeks intervention
|
Changes in the metabolic profile during the intervention will be measured in urine and faecal samples by NMR.
|
12 weeks intervention
|
Changes in faecal water genotoxicity of the volunteers during the intervention by comet assay (single cell gel electrophoresis assay using HT29 cells with Komet 5.5 software)
Time Frame: 12 weeks intervention
|
Genotoxicity of volunteer faecal water will be measured at baseline and during intervention to determine whether prebiotic intervention can ameliorate iron-induced enterocyte genotoxicity.
HT29 cells will be exposed to faecal waters, then single stranded breaks to the DNA will be quantified using Komet 5.5 software.
|
12 weeks intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Daily assessment of stool consistency
Time Frame: 12 weeks intervention
|
Volunteers will keep a daily diary noting the consistency of the stools using the Bristol stool chart.
|
12 weeks intervention
|
Daily assessment of gastrointestinal symptoms
Time Frame: 12 weeks intervention
|
Volunteers will keep a daily diary recording abnormal pain, bloating or flatulence
|
12 weeks intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Simon C Andrews, PhD, University of Reading
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UREC 18/56
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Prebiotic (Synergy-1) + Iron supplement
-
Beneo-InstituteUniversity of ReadingCompletedMoodUnited Kingdom
-
University of CalgaryAlberta Children's HospitalCompletedEffect of Prebiotic Intake on Adiposity, Satiety and Gut Microbiota in Overweight and Obese ChildrenObesity | OverweightCanada
-
Wageningen University and ResearchNexira; Roquette Freres; Bioiberica; Ingredion Incorporated; Naturex; Ministery of... and other collaboratorsCompleted
-
Stanford UniversityAbbottCompletedInflammation | Microbiome | Immune FunctionUnited States
-
January, Inc.Suspended
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
University of GhanaUnknownIron Deficiency Anemia
-
King's College LondonCo-sponsor: Guy's and St Thomas' NHS Foundation TrustCompletedFrailty | Sarcopenia | Age-Related SarcopeniaUnited Kingdom
-
University of Veterinary and Animal Sciences, Lahore...CompletedIron-deficiencyPakistan
-
IBSA Farmaceutici Italia SrlInformapro SrlRecruiting